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The MLH1 polymorphism rs1800734 and
risk of endometrial cancer with
microsatellite instability
Holly Russell1, Katarzyna Kedzierska2, Daniel D. Buchanan3,4,5, Rachael Thomas1, Emma Tham6,7, Miriam Mints8,
Anne Keränen9, Graham G. Giles10,11,12, Melissa C. Southey10,11,12, Roger L. Milne10,11,12, Ian Tomlinson13,
David Church2, Amanda B. Spurdle14, Tracy A. O’Mara14 and Annabelle Lewis1,15*
Abstract
Both colorectal (CRC, 15%) and endometrial cancers (EC, 30%) exhibit microsatellite instability (MSI) due to MLH1
hypermethylation and silencing. The MLH1 promoter polymorphism, rs1800734 is associated with MSI CRC risk,
increased methylation and reduced MLH1 expression. In EC samples, we investigated rs1800734 risk using MSI and
MSS cases and controls. We found no evidence that rs1800734 or other MLH1 SNPs were associated with the risk of
MSI EC. We found the rs1800734 risk allele had no effect on MLH1 methylation or expression in ECs. We propose
that MLH1 hypermethylation occurs by different mechanisms in CRC and EC.
Keywords: Endometrial cancer, Mismatch repair pathway, Microsatellite instability, Single nucleotide polymorphism,
MLH1, rs1800734
Introduction
Endometrial cancer (EC) is the most common gynaeco-
logical cancer in the developed world. Defects in the
mismatch repair (MMR) pathway are common in EC,
with up to 30% of tumours exhibiting loss of expression
of one or more MMR proteins, high levels of microsatel-
lite repeat instability (MSI) and hypermutation [1].
Around 15% of colorectal cancers are MSI and hyper-
mutated [2]. These form a distinct prognostic subset
with early-stage MSI CRCs having a more favourable
outcome than MSS [3, 4], and MSI CRCs responding
well to immunotherapy due to the abundance of neoan-
tigens caused by hypermutation [5, 6]. Therefore, MSI
status in CRC can be used both as an independent
marker of CRC prognosis and a predictor of therapeutic
response. In EC however, despite the prevalence of MSI,
there are conflicting reports about whether or how it is
associated with patient prognosis [1, 7–10]. There is also
a lack of evidence for MSI as a predictive marker of thera-
peutic response in EC, although immunotherapies have
now been approved for use in all MSI- and MMR-
deficient tumours, so this data should be forthcoming
[11].
MutL homologue 1 (MLH1) is the most commonly
disrupted MMR gene in both CRC and EC. This is pre-
dominantly due to somatic silencing by promoter hyper-
methylation in both types of cancer, and less frequently
caused by germline pathogenic variants [12]. In CRC a
promoter polymorphism, rs1800734 in the 5′untrans-
lated region of MLH1 is strongly associated with an in-
creased risk of MSI cancer, as well as hypermethylation
and reduced MLH1 transcription [13–17]. This poly-
morphism has no association with microsatellite stable
(MSS) CRC and shows a much weaker association in
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data sets unstratified by MSI status. Using artificially de-
methylated MSI CRC cell lines heterozygous for
rs1800734, we have previously shown that methylation
accumulation occurs more quickly on the risk (A) allele
than the protective (G) allele and that this is accompan-
ied by an allelic bias in MLH1 transcription, with more
expression from the protective allele [16]. We have sug-
gested that the risk allele is more prone to methylation
accumulation due to disruption of the binding site of
transcription factor TFAP4, which binds strongly to the
protective allele only [16, 18, 19].
In EC, given the prevalence of MSI cancers with MLH1
epigenetic silencing, we also aimed to determine whether
rs1800734 is also associated with the risk of MSI EC.
Existing GWAS studies have not been stratified by MSI
status so any MSI specific associations were unlikely to
have been detected [20]. We performed a candidate asso-
ciation study of single nucleotide polymorphisms (SNPs)
in the MLH1 promoter region in four EC case-control
sample sets stratified by MMR protein expression status.
We have also investigated the effects of rs1800734 geno-
type on MLH1 methylation and expression in ECs. To as-
sess the role of rs1800734 in a dynamic system, we de-
methylated an MSI EC cell line heterozygous for
rs1800734 and studied allele-specific methylation accumu-
lation and MLH1 mRNA expression.
Results and discussion
We inferred MSI status, using MMR protein expression
levels, on patients from four endometrial cancer datasets
previously used for published genome-wide association
studies [20, 21]. We then carried out association analyses
for rs1800734 and 126 other SNPs in a 1Mb region
centred on the MLH1 transcriptional start site on all
MSI and MSS cases vs controls for each study (total
numbers used in the meta-analysis were the following:
MSI n = 225, MSS n = 563, controls n = 13,582, consist-
ing of ANECS-Illumina genotyped, ANECS-iCOGS ge-
notyped, RENDOCAS, MCCS, Fig. 1a; detailed numbers
are broken down in supplementary table 1). We assessed
all the SNPs in the MLH1 promoter and surrounding re-
gions to cover all SNPs in LD with rs1800734 (only 3
SNPs with r2 > 0.5) and allow for the possibility that var-
iants in binding sites of transcription factors (TFs) other
than TFAP4 are more important for regulating MLH1
transcription in endometrial cell types. SNPs within in
silico-predicted TF binding sites, and any known func-
tional role of these TFs in EC, are shown in supplemen-
tary table 2. We carried out a meta-analysis and found
no evidence of MSI EC risk association for rs1800734
(OR = 1.06 CI 0.85–1.33 p = 0.60) or any other SNPs in
the MLH1 region (supplementary table 2), after correc-
tion for multiple testing. While the sample set is rela-
tively small and the findings will need replicating, a
similarly sized MSI CRC sample set gave a strong
rs1800734 risk association (CRC MSI cases n = 170, con-
trols n = 2686, OR = 1.95, 95% CI 1.50–2.55, p = 8.04 ×
10−7, [16]). We estimate that we had 99% power to detect
an OR of this magnitude for MSI EC. However, unlike
CRCs where the majority of sporadic MSI tumours occur
as a result of MLH1 silencing due to promoter hyperme-
thylation [22, 23], a significant proportion of MSI EC oc-
curs as a result of loss of MSH2/MSH6 protein expression
as opposed to MLH1/PMS2 (24% 41/173 from ANECS-
Illumina, ANECS-iCOGS, MCCS). We hypothesized that
the difference in proportion of MLH1 expressing samples
could explain some of the difference in rs1800734 risk as-
sociation between CRC and EC. We therefore carried out
a further meta-analysis (Fig. 1b) selecting only EC samples
with loss of MLH1/PMS2 protein expression and omitting
those in which the MSI was accompanied by loss of
MSH2/MSH6 or where MMR protein expression data
was not available. This focussed meta-analysis also found
no evidence of an association between rs1800734 and
MLH1/PMS2 deficient EC risk (MLH1 loss cases n = 157,
controls n = 13,582, OR = 1.12, CI 0.85–1.46 p = 0.42,
supplementary table 3, power calculations as above indi-
cate a power of 95% with this smaller sample size)
In CRC tumour tissue stratified by genotype (but not
in normal tissue), we previously found that rs1800734
acted as an MLH1 expression quantitative trait locus
(eQTL) and a methylation quantitative trait locus
meQTL (meQTL), with the risk allele associated with
higher methylation and lower mRNA expression [16].
We were therefore interested to see whether this was
true for EC tumours given that there was no association
observed between rs1800734 and EC risk. Using publicly
available data from the Cancer Genome Atlas (TCGA-
UCEC) we assessed the association of rs1800734 status
on MLH1 promoter methylation and MLH1 mRNA ex-
pression, stratified by MSI status (TCGA-UCEC MSI n
= 206; MSS n = 349; Fig. 1c). No significant differences
were found between rs1800734 genotypes for either
methylation or mRNA expression. The MSI samples
were further classified into high-instability levels (MSI-
h) and low (MSI-l) but neither of these subsets showed
any significant differences in methylation or expression
by genotype (supplementary table 4). Due to lack of
complete data on MMR protein expression in TCGA-
UCEC samples, we used MLH1 promoter median
methylation levels (median beta > 0.2) in MSI positive
samples to infer MSI caused specifically by MLH1 loss.
In this subset, no significant differences were found be-
tween rs1800734 genotypes for methylation or mRNA
expression (TCGA-UCEC MSI high methylation n =
135; MSS n = 349; supplementary figure 1). This was
despite a significant negative correlation between MLH1
methylation and mRNA expression levels (Pearson
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Fig. 1 rs1800734 shows no evidence of association with endometrial cancer risk, MLH1 promoter methylation or MLH1 gene expression. a A
forest plot showing a meta-analysis of four rs1800734 endometrial cancer association analyses performed on MSI cases (overall cases = 225,
overall controls = 13582). The plot shows the odds ratio [upper 95% CI, lower 95% CI] of the respective studies. Diamond indicates overall odds
ratio and 95% confidence interval with the p values generated from a fixed-effects meta-analysis showing no evidence of an association for the
rs1800734 SNP with MSI endometrial cancer (p = 0.6). Studies included are as follows: (1) ANECS-Illumina genotyped, (2) ANECS-ICOGS
genotyped, (3) RENDOCAS and (4) MCCS. b A forest plot showing a meta-analysis of four rs1800734 endometrial cancer association analyses
performed on MSI cases which show loss of MLH1/PMS2 proteins but not those showing loss of MSH2/MSH6 (overall cases = 157, overall
controls = 13582). The plot shows the odds ratio [upper 95% CI, lower 95% CI] of the respective studies. Diamond indicates overall odds ratio and
95% confidence interval with the p values generated from a fixed-effects meta-analysis showing no evidence of an association for the rs1800734
SNP with endometrial cancer with loss of MLH1/PMS2 (p = 0.42). Studies included are as follows: (1) ANECS-Illumina genotyped, (2) ANECS-ICOGS
genotyped, (3) RENDOCAS and (4) MCCS. Interestingly, in the RENDOCAS study, rs1800734 does show a significant association with EC; however,
this is based on 25 cases only. c A boxplot of the proportion of methylation proximal to the MLH1 promoter and MLH1 gene expression in EC
patient samples (TCGA-UCEC) stratified by rs1800734 genotype and MSI/MSS status. Methylation beta (β) indicates the median proportion of
methylated to unmethylated reads of 3 CpG probes proximal to MLH1 (probe names: cg00893636, cg02279071, cg13846866). Relative expression
(FPKM-UQ) indicates fragments per kilobase of MLH1 per million mapped reads upper quartile. Plots show the median, upper and lower quartile
of expression or methylation stratified by MSI status and rs1800734 genotype (MSI n = 206, MSS n = 349). rs1800734 genotype had no significant
effect on methylation (p = 0.556 MSS, p = 0.585 MSI; Kruskal-Wallis) or expression (p = 0.434 MSI, Kruskal-Wallis) except for a small set of MSS ECs
with AA genotype (n = 7) in which expression was significantly higher than MSS ECs with the GG genotype (p = 0.045, pairwise Wilcoxon). The
biological significance of this is uncertain
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coefficient = − 0.86, p = 2.2 × 10−16; supplementary fig-
ure 2), supporting the prevailing theory that methylation
is the primary mechanism of MLH1 silencing in EC.
We hypothesized that TFAP4 may not be present in
endometrial tissues and could therefore offer no protec-
tion against promoter methylation accumulation on the
protective rs1800734 allele. However, data from the GTEx
portal showed expression of TFAP4 in uterine tissue at
equivalent or greater levels than intestinal tissues (Com-
mon Fund (CF) Genotype-Tissue Expression Project
(GTEx) dbGaP Study Accession, phs000424.v8.p2). We
therefore checked the activity of the specific TFAP4 bind-
ing site at rs1800734 in endometrial cells by carrying out
chromatin immunoprecipitation in EC cell lines: one MSI
cell line (NOU1, with MLH1 promoter methylation) and
one MSS cell line (HEC1A, Fig. 2a). TFAP4 did bind at or
near rs1800734 in the MSS line and, interestingly, there
was a strong allelic bias in its binding as we and others
previously observed in CRC cells (supplementary figure 3).
As expected, no binding was detected in MSI cells so we
treated with 5 Aza-Cytosine to remove methylation and
then measured MLH1 methylation, expression and TFAP4
binding. Our findings differed substantially from CRC cell
lines. TFAP4 binding was only restored at very low levels
(Fig. 2a). Although some MLH1 re-expression occurred
(Fig. 2b) and promoter methylation was removed and re-
established (Fig. 2c), there was no significant allelic bias in
either expression or methylation at any stage.
Fig. 2 TFAP4 binding occurs in EC cells but does not result in rs1800734 allelic bias of MLH1 expression or promoter methylation. a TFAP1 binds
to MSS but not MLH1 methylated MSI EC cells. The line graph shows relative TFAP4 enrichment at UCSC coordinates proximal to the MLH1
promoter in HEC1A (MSS) cells and NOU1 (MSI) cells untreated and 0 days, 4 days and 11 days post 48 h 5′-azacytidine. Relative TFAP4 enrichment
was determined after normalization with input DNA using the ΔΔCT method. Error bars show the standard error of the mean (n = 3). HEC1A
cells show TFAP4 binding but AzaC treatment did not reactivate TFAP4 expression in Nou1 cells. b MLH1 expression in EC cells shows no
rs1800734 allelic bias. RNA was extracted from HEC1A cells and NOU1 cells, untreated, 0 days, 4 days and 11 days post 48 h 5′-azacytidine
treatment. The bar chart shows relative mRNA expression levels with error bars showing the standard error of the mean (n = 3). Percentages
represent the proportion of G or A reads out of the total rs1800734 sequences for each cell line/time point. NOU1 MLH1 expression is activated
by treatment with 5-azacytidine, with the highest expression 0 days post-treatment. Re-repression occurs at 4 days and 11 days post-treatment.
There is no significant allelic bias at any stage. c 5′-Azacytidine treatment of NOU1 cells removes MLH1 promoter methylation but no allelic bias is
seen in the control or at any post-treatment time point as methylation is re-acquired
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In this small candidate study, our results suggest that
SNP rs1800734 in the MLH1 promoter may not be associ-
ated with risk of MSI EC, even though this SNP shows a
strong association with MSI CRC. This is despite EC and
CRC sharing a common mechanism of epigenetic silen-
cing of MLH1 transcription. The SNP acts as a meQTL
and eQTL in CRC but not in EC. In addition, it has allele-
specific effects on methylation accumulation and mRNA
expression levels in dynamic CRC cell line systems but
not in EC cells. Since both cell types exhibit allele-specific
TFAP4 binding, we conclude that this is not sufficient for
the establishment of meQTL and eQTLs.
Previous findings by Fang et al. [24] have implicated the
transcriptional repressor MAFG and cofactors including
the de novo methylase DNMT3B in the accumulation of
methylation at MLH1 in CRC. MAFG becomes stabilized
by phosphorylation in BRAFV600E mutated cells leading to
hypermethylation at several promoters, including MLH1,
and a CpG island methylator phenotype (CIMP). Interest-
ingly, BRAFV600E mutations occur commonly in somatic
MSI CRC but are very rarely found in MSI EC [25, 26].
Our MSI CRC cell line model (CO-115) but not our MSI
EC model (NOU1) carried a BRAFV600E mutation. This
observation could explain some or all of the differences we
see in rs1800734 and cancer risk association between CRC
and EC and the lack of any genotype-specificMLH1methy-
lation and expression bias in EC tumours and cell lines.
Figure 3 outlines the proposed mechanism to explain
the difference in the role of rs1800734 in CRC and EC.
In the presence of mutant BRAF, TFAP4 and/or cofactor
binding on the protective allele of the SNP reduces
methylation accumulation via MAFG and DNMT3.
However, in EC when no BRAF mutations are present,
the methylation is acquired via a different unknown
mechanism which is unaffected by TFAP4 binding.
Other transcription factors with binding sites upstream
of MLH1, particularly those known to be associated with
EC, merit further investigation.
The pathways to cancer and combination of driver mu-
tations in EC are poorly understood in comparison with
CRC. No EC driver mutations associated with hyperme-
thylation of promoters are currently known so an import-
ant next step is to uncover the key mutations responsible
for MLH1 methylation and CIMP initiation in EC.
Methods
MMR assessment
Tumour MMR expression data was previously generated
by immunohistochemistry (IHC) and assessed as de-
scribed (ANECS [27], RENDOCAS [28], MCCS [29,
30]). Briefly, cases with nuclear staining of all MMR pro-
teins in tumour cells were considered MMR-proficient
and classified as MSS. Cases were reported as MMR-
deficient when tumour cells showed total or partial
Fig. 3 Oncogenic BRAFV600E mutation in colorectal cancer allows MLH1 methylation after TFAP4 disruption. a Colorectal cancer: A BRAFV600E
mutation activates the MEK/ERK pathway to phosphorylate MAFG, allowing DNMT3B recruitment. TFAP4 binding sterically hinders MAFG on the
protective (G) rs1800734 allele, preventing DNMT3B recruitment and subsequent MLH1 methylation. TFAP4 binding is disrupted on the rs1800734
risk (A) allele leading to DNMT3B mediated MLH1 promoter methylation and transcriptional repression. b Endometrial cancer: BRAF is rarely
mutated and MLH1 methylation does not occur via the MAFG pathway. TFAP4 is still able to bind the protective allele but this has no significant
effect on methylation accumulation
Russell et al. Clinical Epigenetics          (2020) 12:102 Page 5 of 9
nuclear loss of expression in one or more of the MMR
proteins and were classified as MSI.
Candidate SNP meta-analysis
GWAS data for meta-analysis was collated from four
endometrial cancer genome-wide association studies [20,
21, 31]—Australian National Endometrial Cancer Stud-
ies (ANECS-Illumina genotyped, ANECS-ICOGS geno-
typed), Registry of Endometrial Cancer in Sweden
(RENDOCAS) and Melbourne Collaborative Cohort
Study (MCCS). IMPUTE2 was used to impute genotypes
to the positive strand of the 1000 Genomes project, v3,
phase 1 dataset. Cases were of European ancestry with a
confirmed EC diagnosis. Genotyping in each study was
performed as previously described [20, 21]: ANECS-
Illumina (MSI n = 66, MSS n = 254, controls n = 3,083)
with Illumina Infinium 610K; ANECS-iCOGS (MSI n =
67, MSS n = 156, controls n = 1,956) and RENDOCAS
(MSI n = 52, MSS n = 88, controls n = 7563) with an
Illumina custom array designed by the Collaborative
Oncological Gene environment Study initiative (iCOGS)
[20] and MCCS (MSI n = 40, MSS n = 65, controls n =
980) with the Illumina OncoArray 534K genotyping
ChIP [21]. Controls were country-matched to cases and
genotyped using the same platforms.
Total numbers used in the meta-analysis were as follows:
MSI n = 225, MSS n = 563 and controls n = 13,582. Quality
control consisted of exclusion of SNPs with < 95% call rates,
MAFs < 1%, duplicated results or related individuals. Com-
prehensive sequencing for germline mutations has not been
completed for all ANECS and RENDOCAS studies so it is
possible a small number (< 3%) of undiagnosed Lynch syn-
drome patients are present in the data. SNPs for this candi-
date study were limited to those within chromosome 3,
1Mb upstream and downstream of MLH1 transcriptional
start site (chr3:36,000,000–38,000,000 hg38; chr3:36024996–
38024996 hg19). rs1800734 was directly genotyped in all
datasets. To determine if our dataset (MSI and controls) was
of a sufficient size, power calculations based on our CRC as-
sociation study (OR = 1.95, MAF of 0.2, n = 13807, case rate
= 0.016) indicated a power of 99% to discover a similar asso-
ciation to that seen in CRC. Using a more conservative OR
of 1.4 in the same calculation indicated a power of 85%. As-
sociation statistics from individual GWAS’s were entered
into PLINK 1.9 for a fixed-effects meta-analysis. P-threshold
for candidate significance was 0.05. Standard Bonferroni
methods were used to correct P-threshold for multiple test-
ing. Confidence intervals are set at 95%.
TCGA-UCEC analysis
TCGA-UCEC methylation, gene expression data and
MSI status were downloaded from the GDC portal
(https://portal.gdc.cancer.gov/) using the GDC toolkit.
The rs1800734 genotype was extracted from TCGA-
UCEC whole genome sequencing sliced BAM files using
Platypus variant calling software [24]. Data was down-
loaded, collated and pre-analysed using a custom script
available on GitHub (https://github.com/kzkedzierska/
mlh1_endo). For MLH1 promoter methylation, the beta
median methylation level for CpG residues proximal (±
2000 bp) to rs1800734 was calculated. MLH1 transcript
fragments per kilobase per million mapped reads upper
quartile (FPKM-UQ) was used as a measure of expres-
sion. Samples with any missing values were excluded be-
fore data visualization and statistical analysis in R (MSI
n = 206; MSS n = 349).
Cell lines
HEC1A and NOU1 cells were maintained in Dulbecco’s
modified eagle medium (Gibco™), 10% FBS, 0.1%
penicillin-streptomycin. rs1800734 was genotyped using
KASPARTM technology (LGC) according to the manu-
facturer’s instructions using specific primers (Supple-
mentary table 5).
Analysis of methylation
DNA was extracted from fresh cells using the DNeasy
kit (QIAGEN). Bisulphite conversion of DNA was car-
ried out using the EZ DNA methylation kit (Zymo Re-
search) according to the manufacturer’s instructions.
Converted DNA was amplified with Pyromark PCR kit
(Qiagen) using CpG free primers (Supplementary table
5) with Illumina-specific sequence tags to ensure un-
biased amplification of methylated and unmethylated
template. Amplicons from each sample were barcoded
together using a custom set of index tags and primers
[32]. Sequencing was carried out using a 250-bp paired
end kit on a MiSeq (Illumina) according to the manufac-
turer’s instructions. MiSeq output was demultiplexed
and FASTQ files generated (Basespace, Illumina). The
sequences were quality assessed and trimmed (FastQC
and TrimGalore, Babraham Bioinformatics) then aligned
and the methylation called by rs1800734 allele (Bismark,
Babraham Bioinformatics).
Analysis of mRNA
RNA was extracted from fresh cells using the RNeasy kit
(QIAGEN) and cDNA was generated (High Capacity
cDNA Reverse Transcription Kit, Applied Biosystems)
according to the manufacturer’s instructions. Gene ex-
pression was quantified and normalized using Taqman
gene expression ready mixed assays (Applied Biosystems,
Thermofisher). Allele-specific MLH1 expression was
assessed by amplification of cDNA using Illumina tagged
primers (Supplementary table 5) followed by NGS se-
quencing on a MiSeq (Illumina) as above. Trimmed
FastQ sequences were aligned using bwa-mem and the
rs1800734 variant called by Platypus [33].
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Chromatin Immunoprecipitation
Approximately 108 cells were crosslinked for 10 min
with 1% formaldehyde, neutralized with 125mM glycine,
washed with ice-cold PBS and scraped. After 2 further
PBS washes, cells were resuspended in lysis buffer, (1%
SDS, 10 mM EDTA, 50mM Tris-HCl, protease inhibi-
tors) sonicated using a Bioruptor (Diagenode) for 7-15 x
15 s cycles, centrifuged at max speed for 10 min at 4 °C
and diluted 1:10 in IP dilution buffer (1% triton-100, 2
mM EDTA, 150 mM NaCl, 20 mM Tris). Immunopre-
cipitation (IP) with 5 μg of antibody (anti-TFAP4 Santa
Cruz Biotechnology, sc-18593X) was carried out over-
night at 4 °C and then incubated for 4 h with 50 μl of
protein G Dynabeads (Invitrogen). For each chromatin
sample, a mock IP with no antibody was carried out in
parallel with the TFAP4 IP, and for all subsequent steps
of the assay, as a negative control. Bead/antibody and
mock complexes were washed with TSEI (0.1% SDS, 1%
TritonX-100, 2 mM EDTA, 20 mM Tris, 150 mM NaCl),
TSEII (0.1% SDS, 1% TritonX-100, 2 mM EDTA, 20mM
Tris, 500 mM NaCl), LiCl buffer (0.25LiCl, 1% NP-40,
1% deoxycholate, 1 mM EDTA, 10mM Tris-HCl) and
TE according to standard protocols and eluted with 1%
SDS, 0.1M NaHCO3. One microliter of DNA was ana-
lysed in duplicate or triplicate by SYBR green qPCR
using PowerUp SYBR™ Green Master Mix (Thermo-
fisher) and primers covering the MLH1 promoter region
(Supplementary Table 6). The results were calculated
with the ΔΔCT method using Ct values from the input
chromatin to normalize (ΔCT) and then expressed rela-
tive to a primer set outside the TFAP4 binding site
(ΔΔCt) and the relative fold change calculated using the
equation 2−ΔΔCt. No amplification was observed from
DNA extracted from the mock IPs.
5-Aza-2′-deoxycytidine treatment
Adherent semiconfluent MSI NOU1 cells in exponential
growth were treated with 5uM 5-Aza-2′-deoxycytidine
in standard medium (AzaC, Sigma A3656) for 48 h (with
replenishment of AzaC after 24 h). AzaC was removed
and cells washed with PBS and then cultured in standard
medium for 0, 4, 7 and 11 days. RNA and DNA were ex-
tracted simultaneously using the AllPrep kit (Qiagen)
and MLH1 mRNA expression and promoter methylation
assessed as described above. ChIP was carried out post
AzaC treatment as described above.
Plots and statistics
R software and associated packages (tidyverse, gridExtra,
ggplot2, ggsci, dylpr and ggforce) were used to generate
all graphs and carry out statistical tests including
ANOVA, Tukey, Kruskal-Wallis, paired Wilcoxon, t test
and Pearson’s. Power calculations were carried out using
the genpwr package
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13148-020-00889-3.
Additional file 1: Supplementary figure 1. A Boxplot of the
proportion of methylation proximal to the MLH1 promoter and MLH1
gene expression in EC patient samples (TCGA-UCEC) stratified by
rs1800734 genotype and MSI with high MLH1 methylation (median Beta
>0.2) and MSS status. Supplementary figure 2: MLH1 expression of MSI
samples inversely correlates with promoter methylation. Supplementary
figure 3: In HEC1A cells TFAP4 binds preferentially to the rs1800734 G
allele. Supplementary table 1: Sample numbers and minor allele
frequency for rs1800734 for each data set. Supplementary table 4:
Statistical test p-values on genotype vs methylation and genotype vs ex-
pression associations in TCGA-UEAC sample subsets. Supplementary table
5: Primers used for genotyping, amplicon bisulphite sequencing and
cDNA amplification. Supplementary table 6: Primers used for Q-PCR
(SYBR) amplification of ChIP DNA.
Additional file 2: Supplementary figure 2. Results of meta-analysis of
all MSI cases versus controls (from ANECS – Illumina genotyped, ANECS –
iCOGS genotyped, RENDOCAS, MCCS; MSI n = 225, controls n = 13,582)
showing association statistics for all SNPs in the MLH1 promoter region
(chr3:36,000,000-38,000,000 hg38; chr3:36024996-38024996 hg19) and in
silico predicted transcription factor binding sites (SNP2TFBS).
Additional file 3: Supplementary figure 3. Results of meta-analysis of
cases with loss of MLH1/PMS2 protein expression only versus controls
(from ANECS – Illumina genotyped, ANECS – iCOGS genotyped, RENDO-
CAS, MCCS; MLH1 loss cases n = 157, controls n = 13,582) showing asso-
ciation statistics for all SNPs in the MLH1 promoter region
(chr3:36,000,000-38,000,000 hg38; chr3:36024996-38024996 hg19).
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